newsfilter
← Latest News
GlobeNewswire·

Belite Bio Announces Extension of FDA Review Timeline for Tinlarebant NDA

  • Belite Bio announced the FDA extended the review period for its New Drug Application (NDA) for tinlarebant by three months.
  • The new Prescription Drug User Fee Act (PDUFA) action date is set for May 12, 2027.
  • The FDA plans to communicate proposed labeling requests & any anticipated postmarketing requirement requests by April 12, 2027, if no major deficiencies are found.
  • Tinlarebant is an oral therapy intended to reduce bisretinoid toxin accumulation in Stargardt disease type 1 (STGD1) & geographic atrophy (GA).
  • The drug has received Breakthrough Therapy Designation, Fast Track Designation, Rare Pediatric Disease Designation, Orphan Drug Designation, & Sakigake Designation for STGD1.
  • Belite Bio completed the Phase 3 DRAGON trial for STGD1 which met its primary endpoint.
  • The company is currently evaluating tinlarebant in the Phase 2/3 DRAGON II trial for STGD1 & the Phase 3 PHOENIX trial for GA.
Company
Belite Bio, Inc
Keywords
Nasdaq:BLTE, Belite Bio, Inc